tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ONC Stock Latest News

BeOne Medicines: Strong Financial Performance and Promising Pipeline Drive Buy Rating
RatingsBeOne Medicines: Strong Financial Performance and Promising Pipeline Drive Buy Rating
5d ago
ONC
BeOne Medicines price target raised to $350 from $340 at BofA
PremiumThe Fly
BeOne Medicines price target raised to $350 from $340 at BofA
6d ago
ONC
BeOne Medicines price target raised to $360 from $334 at TD Cowen
PremiumThe Fly
BeOne Medicines price target raised to $360 from $334 at TD Cowen
6d ago
ONC
AMGN
BeOne Medicines: Strong Financial Performance and Strategic Positioning Justify Buy Rating
PremiumRatings
BeOne Medicines: Strong Financial Performance and Strategic Positioning Justify Buy Rating
6d ago
ONC
BeOne Medicines Reports Strong Q2 2025 Performance
PremiumCompany Announcements
BeOne Medicines Reports Strong Q2 2025 Performance
6d ago
ONC
BeiGene’s Earnings Call Highlights Robust Growth and Market Leadership
PremiumCompany AnnouncementsBeiGene’s Earnings Call Highlights Robust Growth and Market Leadership
6d ago
ONC
BeOne Medicines: Strong Financial Performance and Promising Pipeline Justify Buy Rating and Increased Price Target
Premium
Ratings
BeOne Medicines: Strong Financial Performance and Promising Pipeline Justify Buy Rating and Increased Price Target
6d ago
ONC
BeOne Medicines narrows FY25 revenue view to $5.0B-$5.3B from $4.9B-$5.3B
Premium
The Fly
BeOne Medicines narrows FY25 revenue view to $5.0B-$5.3B from $4.9B-$5.3B
7d ago
ONC
BeOne Medicines reports Q2 EPS 6c vs. (9c) last year
PremiumThe Fly
BeOne Medicines reports Q2 EPS 6c vs. (9c) last year
7d ago
ONC
BeOne Medicines granted PRIME designation for BGB-16673 by EMA
PremiumThe Fly
BeOne Medicines granted PRIME designation for BGB-16673 by EMA
13d ago
ONC
BeOne Medicines reports positive opinion from CHMP regarding TEVIMBRA
PremiumThe Fly
BeOne Medicines reports positive opinion from CHMP regarding TEVIMBRA
16d ago
ONC
BeOne Medicines price target raised to $345 from $321 at JPMorgan
PremiumThe Fly
BeOne Medicines price target raised to $345 from $321 at JPMorgan
27d ago
ONC
BeOne Medicines price target raised to $349 from $311 at RBC Capital
PremiumThe FlyBeOne Medicines price target raised to $349 from $311 at RBC Capital
28d ago
ONC
BeOne announces EC approval of Tevimbra in combination with chemotherapy
Premium
The Fly
BeOne announces EC approval of Tevimbra in combination with chemotherapy
1M ago
ONC
Buy Rating for BeOne Medicines: Promising Developments and Strategic Positioning
Premium
Ratings
Buy Rating for BeOne Medicines: Promising Developments and Strategic Positioning
1M ago
ONC
Beigene’s BG-68501 Study: A Potential Game-Changer in Oncology
PremiumCompany Announcements
Beigene’s BG-68501 Study: A Potential Game-Changer in Oncology
1M ago
ONC
Jazz Pharmaceuticals and BeiGene’s Promising Phase 3 Study for Advanced Gastric and Esophageal Cancers
PremiumCompany Announcements
Jazz Pharmaceuticals and BeiGene’s Promising Phase 3 Study for Advanced Gastric and Esophageal Cancers
2M ago
ONC
JAZZ
BeiGene’s Promising Phase 2 Study on Waldenström Macroglobulinemia
PremiumCompany Announcements
BeiGene’s Promising Phase 2 Study on Waldenström Macroglobulinemia
2M ago
ONC
BeOne Medicines price target raised to $330 from $313 at Morgan Stanley
PremiumThe Fly
BeOne Medicines price target raised to $330 from $313 at Morgan Stanley
2M ago
ONC
BeOne Medicines price target raised to $321 from $317 at JPMorgan
PremiumThe FlyBeOne Medicines price target raised to $321 from $317 at JPMorgan
2M ago
ONC
BeiGene’s Robust Oncology Pipeline and Strategic Developments Justify Buy Rating with $300 Price Target
Premium
Ratings
BeiGene’s Robust Oncology Pipeline and Strategic Developments Justify Buy Rating with $300 Price Target
2M ago
ONC
Beigene’s Promising Phase 1 Study on BGB-21447 for Metastatic Breast Cancer
Premium
Company Announcements
Beigene’s Promising Phase 1 Study on BGB-21447 for Metastatic Breast Cancer
2M ago
ONC

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >